Zometa is indicated for:
- Prevention of skeletal related events (SRE*) in adult patients with advanced malignancies involving bone.
- Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
*SRE = skeletal related event: defined as pathological fracture, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia (TIH).
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
To contact us in your country of residence, please click here